QGEN241220P50000
- 0.00
- 0.000.00%
Qiagen NV Newsroom
BofA Securities Maintains Qiagen NV(QGEN.US) With Buy Rating
QIAGEN Stock Gains Following the Latest Launch of IPA Interpret
QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data
Top Gap Ups and Downs on Tuesday: GOOG, ALK, ORCL and More
S&P 500 Futures Up In Premarket Trading; Oracle, Ferguson Enterprises Lag
Qiagen N.V. (NYSE:QGEN) Is a Favorite Amongst Institutional Investors Who Own 82%
Qiagen Coverage Assumed by Jefferies at Buy Vs Previous Rating of Hold
Qiagen Analyst Ratings
Jefferies Initiates Qiagen NV(QGEN.US) With Buy Rating, Announces Target Price $54
QIAGEN Stock Might Rise Following 1000 EZ2 Connect Placements
QIAGEN Achieves Milestone With Over 1,000 Placements Of EZ2 Connect Sample Preparation Instrument
Should You Continue to Retain QIAGEN Stock in Your Portfolio Now?
Qiagen Plans to Open New Facility in Spain in 2026
QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing
QIAGEN Launches Novel Tools for Customizing Digital PCR Assays and NGS Panels for Microbial Analysis
Qiagen N.V.'s (NYSE:QGEN) Intrinsic Value Is Potentially 43% Above Its Share Price
Innovations Support QIAGEN Shares Despite Macroeconomic Concerns
Morgan Stanley Lists Hedge Funds' Largest Q3 Ownership Increases in Russell 1000 Stocks
Syros Pharmaceuticals Gave Notice To Qiagen Manchester Limited Of Its Election To Terminate The Master Collaboration Agreement Dated March 7, 2022
Catalyst Watch: Nvidia Earnings, Microsoft Ignite, Crypto Confidence, and P&G Event